Medicine and Dentistry
Cytoreductive Surgery
100%
Hyperthermic Intraperitoneal Chemotherapy
92%
Surgery
80%
Cancer
75%
Neoplasm
50%
Oncologist
47%
Carcinomatous Peritonitis
40%
Disease
36%
Hepatocellular Carcinoma
36%
Hepatectomy
30%
Recurrent Disease
29%
Peritoneum Metastasis
27%
Overall Survival
23%
Pathologist
23%
Symptomatic Treatment
23%
Awareness
21%
Metastatic Carcinoma
21%
Colorectal Carcinoma
20%
Peritoneum Cancer
18%
Cholangiocarcinoma
17%
Intraperitoneal Chemotherapy
15%
Adenocarcinoma
13%
Malignant Neoplasm
12%
Gallbladder Cancer
11%
Neuroendocrine Tumor
11%
Abdominal Cancer
10%
Surgeon
10%
Neoadjuvant Therapy
10%
Peritoneum Mesothelioma
9%
Pancreas Adenocarcinoma
9%
Diseases
9%
Recurrence Free Survival
8%
Appendix Tumor
8%
Multivariate Analysis
8%
Chemotherapy
8%
Hepatitis B
7%
Pancreas Cancer
7%
Postoperative Complication
7%
Lung Metastasis
7%
Metastasectomy
7%
Patient Selection
7%
Diagnosis
7%
Surgery
7%
Survival Rate
6%
Neoadjuvant Chemotherapy
6%
Laparoscopic Surgery
6%
Surgical Oncology
6%
Liver Metastasis
6%
Mortality Rate
6%
Percutaneous Coronary Intervention
5%
Keyphrases
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
99%
Cytoreductive Surgery
86%
Peritoneal Surface Malignancy
59%
Resection
49%
Chicago
47%
Peritoneal Carcinomatosis
39%
Hepatocellular Carcinoma
31%
Pathologist
24%
Radiologists
23%
Medical Oncologist
23%
Surgical Oncologist
23%
Peritoneal Surface Disease
23%
Palliative Care Physicians
23%
Pharmacist
23%
Appropriate Management
23%
Enhanced Awareness
23%
Peritoneal Metastasis
18%
Peritoneal Cancer Index
18%
Overall Survival
16%
Tumor
15%
Surgical Management
13%
Surgical Resection
13%
Gallbladder Cancer
13%
Gastric Cancer
13%
Patient Selection
12%
Liver
11%
Systemic Chemotherapy
11%
5-year Survival
11%
Appendiceal
11%
Liver Resection
10%
Secondary Cytoreductive Surgery
10%
Colorectal Cancer
9%
Hepatic Resection
9%
Postoperative Outcomes
9%
Colorectal Metastases
9%
Long-term Survival
9%
Postoperative Mortality
8%
Oncological Outcomes
8%
Recurrence-free Survival
8%
Pancreatic Ductal Adenocarcinoma
8%
Consensus Guidelines
8%
Multivariate Analysis
8%
Appendiceal Neoplasms
8%
Pancreatic Cancer
7%
Hepatitis B
7%
Peritoneal Mesothelioma
7%
Malignancy
7%
Cholangiocarcinoma
7%
Metastasis
6%
Patients with Colorectal Cancer
6%